The Women's Screening and Self-Testing Program (PROMETA) Study

Not yet recruitingOBSERVATIONAL
Enrollment

8,400

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2031

Study Completion Date

January 31, 2031

Conditions
Human Papilloma Virus Related Cervical Carcinoma
Interventions
DIAGNOSTIC_TEST

Cervical Cancer Screen-Triage-Treat Care Cascade

Cervical Cancer Screen-Triage-Treat Care Cascade: After providing informed consent, the study clinician will open a Case Report Form (CRF) for each patient which starts with a brief questionnaire, which will include the participant's demographic information and medical history, including HIV viral load and cluster of differentiation 4 (CD4) counts, previous cervical cancer screening results if previously screened, and result of rapid pregnancy test performed that day. Each participant will then be accompanied to a private location where the study nurse will provide counseling and instruction on how to appropriately perform the self-collection vaginal swab technique.

Trial Locations (1)

Unknown

University Eduardo Mondlane (UEM), Maputo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Tulane University

OTHER

NCT06810739 - The Women's Screening and Self-Testing Program (PROMETA) Study | Biotech Hunter | Biotech Hunter